Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoints_Thomas Slavin
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Thomas Slavin Shares Insights on the Data Validating Breast Cancer PRS Across Ancestries

In an interview with PharmaShots, Dr. Thomas Slavin, M.D, Senior Vice President of Medical Affairs, Oncology at Myriad Genetics and study co-author shared his views on the data presented at ASCO 2021 and its implications for women.Shots:Myriad Genetics data helps more women to control their health by helping them understand their lifetime risk of developing…
June 22, 20210Comments

Read more

Viewpoints_Dr. Bob Deans
VIEWPOINTS

PharmaShots Interview: Synthego’s Dr. Bob Deans Shares Insights on the Launch of its Eclipse Platform for Drug Discovery

In an interview with PharmaShots, Dr. Bob Deans, Chief Scientific Officer at Synthego shares insights on the wide availability of its new CRISPR-based platform, Eclipse. Synthego created the Eclipse platform to enhance disease modeling, drug target identification, and validation, and accelerate cell therapy manufacturing.Shots:Eclipse uses MLto apply experience from several hundred thousand genome edits across…
June 22, 20210Comments

Read more

Viewpoints_Nan Li
VIEWPOINTS

PharmaShots Interview: Janssen’s Nan Li Shares Insights on the Data Presented at ISPOR 2021

In an interview with PharmaShots, Nan Li, Director of Access, Janssen Retina DAS shared her views on the attempts to quantify the economic burden of X-linked retinitis pigmentosa and achromatopsia.Shots:Janssen presented two posters on the economic burden and impact on people living with inherited retinal diseases X-linked retinitis pigmentosa (XLRP) and achromatopsia at ISPOR 2021…
June 21, 20210Comments

Read more

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress
EVENTS

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress

Event description: Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th June - 1st July 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers, and scientists from research institute pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC's,…
June 15, 20210Comments

Read more

Viewpoints_Dr. Stanley T. Crooke
VIEWPOINTS

PharmaShots Interview: n-Lorem Foundation’s Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients

In an interview with PharmaShots, Dr. Stanley T. Crooke, Founder, and Chief Executive Officer and Chairman of the Board at n-Lorem Foundation share his views on the collaboration with Ultragenyx.Shots:n-Lorem Foundation is the first & only foundation of its kind with a mission to provide life-saving treatments to patients who have diseases caused by extremely rare…
June 15, 20210Comments

Read more

Viewpoints_Dr. Maria Ines Mitrani
VIEWPOINTS

PharmaShots Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19

In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India.Shots:This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, which has entered into a product testing and distribution agreement with Organicell…
June 15, 20210Comments

Read more

Viewpoints_Dr. Malcolm Barratt-Johnson
VIEWPOINTS

PharmaShots Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies

In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic therapies, the company's business model, and your plans for scaling the psychedelics therapies.Shots:Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access to patients…
June 11, 20210Comments

Read more

Viewpoints_Federico Grossi
VIEWPOINTS

PharmaShots Interview: Apellis’ Federico Grossi Shares Insights on the Data in GA Presented at ARVO 2021

In an interview with PharmaShots, Apellis' Chief Medical Officer, Federico Grossi shares his views on the data presented at ARVO 2021. The studies support AI analytics as a tool to distinctly measure disease activity well as the therapeutic effect in GA.Shots:Apellis presented five oral presentations from an AI collaboration with the Ophthalmic Imaging Analysis (OPTIMA)…
June 9, 20210Comments

Read more